AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.72 |
Market Cap | 190.75M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.12 |
PE Ratio (ttm) | -0.88 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.78 |
Volume | 54,173 |
Avg. Volume (20D) | 338,983 |
Open | 2.70 |
Previous Close | 2.66 |
Day's Range | 2.68 - 2.83 |
52-Week Range | 1.12 - 4.20 |
Beta | undefined |
About IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic const...
Analyst Forecast
According to 2 analyst ratings, the average rating for IKT stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 136.36% from the latest price.
1 month ago · seekingalpha.com
Inhibikase: Potential To Improve Current Treatment Options For PAH PatientsThe company received FDA approval to initiate a late-stage study of IKT-001Pro for pulmonary arterial hypertension, backed by $275 million in funding. IKT-001Pro, a modified version of imatinib, aims ...